Purchase Order 75N95022P00047
Award Date 12/7/21
Potential Completion Date 12/6/22
Potential Value $167K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Malvern, PA 19355, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Drug Abuse to Reaction Biology Corporation, a self-certified small disadvantaged business. The $143,260.00 contract is for kinase screening services, with Reaction Biology testing 377 wild-type kinases against 10 compounds. The award stems from a non-competitive solicitation issued by the NIH's National Center for Advancing Translational...
- This is a firm fixed-price purchase order contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the National Institutes of Health (NIH), to Reaction Biology Corporation, a self-certified small disadvantaged business. The $102,100 contract is for testing 10 novel small molecule compounds against a panel of 50 wild-type kinases, as well as testing 5 compounds against a more comprehensive panel of 374 wild-type kinases. The purpose is to assess the kinase...
- This $125,600.00 firm fixed-price purchase order was awarded by the National Institutes of Health's National Center for Advancing Translational Sciences to Reaction Biology Corporation, a self-certified small disadvantaged business, to conduct testing of novel small molecule compounds for kinase inhibition. The contract does not have a set-aside designation. The work involves screening 300 compounds against 3 wild-type kinases and 10 compounds against a panel of 50 wild-type kinases using...
- This is a $118,430.00 firm fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences to Reaction Biology Corporation, a self-certified small disadvantaged business. The contract is for testing 15 novel small molecule compounds using Reaction Biology's proprietary Kinase HotSpot assay platform. This work supports translational research efforts across the NIH. The purchase order was...
- This is a firm fixed-price purchase order awarded by the National Institutes of Health's National Center for Advancing Translational Sciences to Reaction Biology Corporation, a self-certified small disadvantaged business. The $21,027.68 contract is for the testing of 2 compounds against a selected kinase panel in a biochemical gamma 33P-ATP kinase assay. Reaction Biology specializes in enzyme activity assays and has previously provided kinase inhibition testing, cancer cell line screening, and...
- This $34,884 fixed-price purchase order was awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to Reaction Biology Corporation, a small disadvantaged business, to conduct kinase inhibition testing on 100 novel small molecule compounds. The contract supports the work of the National Center for Advancing Translational Sciences (NCATS) within NIH, which is focused on developing potential anti-cancer agents. Reaction Biology will use its...
- This federal contract award from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), was issued to Reaction Biology Corporation, a self-certified small disadvantaged business based in Malvern, PA. The $150,330 firm-fixed-price purchase order contract requires Reaction Biology to provide compound testing services, including screening 10 small molecule compounds against a panel of 50 kinases and 5 compounds against a panel of 374 kinases using the Kinase...
- Reaction Biology Corporation was awarded a $16,480.80 firm fixed price purchase order by the National Institutes of Health's National Center for Advancing Translational Sciences to test 35 novel small molecule compounds for inhibition of three wild-type kinase enzymes. Under the contract, Reaction Biology will utilize its Kinase HotSpot assay platform to test each compound at 10 different doses and provide one comprehensive report detailing results against the three kinases. The testing services...
- Reaction Biology Corporation was awarded a $109,470 firm fixed price purchase order by the Department of Health and Human Services' National Institutes of Health's National Institute on Drug Abuse to provide compound testing services in support of kinase enzyme inhibition and cardiac ion channel block research. As the prime contractor, Reaction Biology will test 330 small molecule compounds using its Kinase HotSpot and automated patch-clamp assay platforms to characterize inhibition of kinase...
- This federal contract was awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to Reaction Biology Corporation, a small disadvantaged business based in Malvern, Pennsylvania. The $120,601.79 firm fixed-price contract involves the provision of specialized scientific testing services, such as enzyme activity assays, screening, and related testing for biomedical research initiatives. The contract supports NIDA's translational research...